<DOC> 
<DOCNO>1071011_business_story_8420215.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
Archives
				 Lupin picks up majority stake in Japan firm
 OUR CORRESPONDENT																								Mumbai, Oct. 10: Drug maker Lupin Ltd has acquired a majority stake in Japan-based Kyowa Pharmaceutical Industry Co Ltd for $60 million. 																								Kyowa, which registered sales of 7.4 billion yen for the year ended March 2007, develops, manufactures and markets generic drugs against psychiatric and neurological disorders as well as for cardiovascular, respiratory and digestive systems. 																								Lupin chairman Desh Bandhu Gupta said, This is a significant part of our strategy to establish a beachhead in the second-largest pharmaceutical market in the world. Kyowa has strengths in developing, manufacturing and marketing its products nationwide. Lupin will be able to add value through its strengths in R amp;D and global marketing. This acquisition is a signal of our long-term commitment to the Japanese healthcare market. 																								Kyowa chairman Y. Sugiura said, I am delighted that Lupin is acquiring a majority stake in Kyowa and I am sure that with its global vision, Lupin will be able to propel Kyowa to the top league in Japan.																								In September, Lupin acquired Baroda-based Rubamin Laboratories Ltd, part of the Rubamin group. Rubamin Laboratories manufactures advanced intermediates for active pharmaceutical ingredients under the contract research and manufacturing model. 
</TEXT> 
</DOC>